Introduction
Patients and methods
Results
Characteristica | PAE (N = 25) | TURP (N = 25) |
---|---|---|
Age, years | 62.9 ± 7.5 | 63.1 ± 9.0 |
Body-mass-index, kg m−2 | 25.8 ± 3.5 | 26.8 ± 3.2 |
Charlson comorbidity index | 3.2 ± 1.2 | 4.0 ± 2.1 |
Prostate volume (transabdominal ultrasound), mL | 50.6 ± 16.3 | 52.1 ± 20.1 |
Prostate volume (magnetic resonance imaging), mL | 49.8 ± 31.8 | 59.7 ± 35.3 |
Medical treatment of LUTS prior to surgery, no. (%) | ||
5-Alpha-reductase inhibitors alone | 0 (0%) | 0 (0%) |
Alpha1-adrenergic receptor antagonists | 12 (48%) | 12 (48%) |
Combination of the two above | 7 (28%) | 4 (16%) |
Total patients with drug treatment | 19 (76%) | 16 (64%) |
Indwelling urethral catheter at baseline, no. (%) | 4 (16%) | 3 (12%) |
Patient no. | ||||||
---|---|---|---|---|---|---|
Localization | Findings | 1 | 2 | 3 | 4 | 5 |
Prostate—central gland | Necrosis/fibrosis/hemorrhage | +++ | +++ | +++ | +++ (anterior) ++ (posterior) | +++ (anterior) ++ (posterior) |
Particles | ++ | +++ | ++ | ++ | +++ (anterior) ++ (posterior) | |
Prostate—peripheral gland | Necrosis/fibrosis/hemorrhage | + | ++ (anterior) + (posterior) | +++ (anterior) ++ (posterior) | +++ (anterior) ++ (posterior) | ++ |
Particles | + | +++ (anterior) + (posterior) | +++ | ++ (anterior) + (posterior) | +++ | |
Particles in adjacent soft tissue | ++ | +++ (anterior) ++ (posterior) | +++ | +++ (anterior) ++ (posterior) | + (anterior) +++ (posterior) | |
Prostate—adjacent to verumontanum | Necrosis/fibrosis/hemorrhage | + | + | ++ | ++ | ++ |
Particles | + | +++ | + | ++ | ++ | |
Ejaculatory ducts | Necrosis/fibrosis/hemorrhage | ++ | ++ | ++ | +++ | ++ |
Particles | + | + | 0 | ++ | + | |
Particles in adjacent soft tissue | ++ | + | ++ | 0 | 0 | |
Seminal vesicles | Necrosis/fibrosis/hemorrhage | +++ | ++ | +++ | +++ | ++ |
Particles | + | + | + | ++ | +++ | |
Particles in adjacent soft tissue | ++ | + | ++ | +++ | ++ |